Vínculo: A Digital Intervention for Anxiety, Depression, and Insomnia Symptoms (VINCULO-ADI)

November 15, 2026 updated by: Renatha El Rafihi-Ferreira, University of Sao Paulo

Vínculo: A Randomized Controlled Trial of a Guided Digital Intervention for Anxiety, Depression, and Insomnia Symptoms

Insomnia, anxiety, and depression are common mental health problems that frequently occur together. Psychological interventions that address shared processes underlying these symptoms may offer an accessible way to improve mental health and sleep.

This study will evaluate the effectiveness of Vínculo, an eight-week, guided digital psychological intervention for adults experiencing clinically significant symptoms of insomnia, anxiety, and/or depression.

Approximately 305 adults living in Brazil will be randomly assigned to one of two groups. The experimental group will receive Vínculo, a psychological intervention delivered through a WhatsApp chatbot that combines acceptance and commitment therapy, behavioral activation, and behavioral strategies for sleep. The comparison group will receive an eight-week digital psychoeducation program covering mental health, emotions, sleep, and healthy lifestyle habits.

Both groups will receive structured content through WhatsApp, three individual videoconference sessions with a psychologist, and access to asynchronous psychological support during the intervention.

The main objective is to determine whether Vínculo is more effective than digital psychoeducation in reducing insomnia severity, depressive symptoms, and anxiety symptoms after eight weeks. Participants will also be assessed three and six months after the intervention to examine whether improvements are maintained. Additional assessments will examine daily functioning and psychological processes related to treatment outcomes.

Study Overview

Status

Not yet recruiting

Conditions

Intervention / Treatment

Detailed Description

This study is a fully remote, open-label, two-arm, parallel-group randomized controlled trial designed to evaluate the efficacy of Vínculo, a guided digital transdiagnostic psychological intervention, compared with an active digital psychoeducation control condition.

The study will enroll approximately 305 adults aged 18-59 years living in Brazil who report clinically significant symptoms in at least one of three domains: insomnia, depression, or anxiety. Eligibility will be established through electronic screening followed by a structured clinical assessment. A formal psychiatric diagnosis will not be required for inclusion.

After baseline assessment, participants will be randomized in a 1:1 ratio using computer-generated, randomly permuted blocks of varying sizes. Randomization will be stratified according to eight possible baseline symptom profiles, defined by the presence or absence of clinically significant insomnia, depression, and anxiety symptoms. Allocation will be implemented through REDCap.

The experimental intervention is based on process-based therapy and integrates components of acceptance and commitment therapy, behavioral activation, and behavioral strategies for insomnia. Therapeutic content will address emotional awareness, experiential avoidance, mindfulness, values clarification, committed action, behavioral activation, acceptance, cognitive defusion, sleep-related behaviors, and relapse prevention. Behavioral sleep strategies will be introduced in Week 4 and will not include sleep restriction.

The active control condition will provide structured psychoeducation about mental health, emotional symptoms, sleep, and healthy lifestyle habits without introducing the specific therapeutic techniques of the experimental intervention.

Both conditions will last eight weeks. Structured digital content will be delivered through WhatsApp three times weekly, with reminders on alternate days. Participants in both groups will receive three individual videoconference sessions with a psychologist and access to asynchronous professional support on business days. The content of professional support will be specific to each assigned condition.

The three co-primary outcomes are insomnia severity, depressive symptoms, and anxiety symptoms, assessed one week after completion of the eight-week intervention using the Insomnia Severity Index (ISI), Patient Health Questionnaire-9 (PHQ-9), and Generalized Anxiety Disorder-7 (GAD-7), respectively.

Secondary assessments will examine symptom severity at three- and six-month follow-ups, functional impairment, clinical response, behavioral activation, and psychological flexibility. Exploratory assessments will address anhedonia and working alliance.

The primary analyses will compare treatment groups while accounting for baseline symptom severity. The study will also investigate treatment effects across different baseline symptom presentations and evaluate changes in psychological processes associated with clinical outcomes.

Study Type

Interventional

Enrollment (Estimated)

305

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

    • São Paulo
      • São Paulo, São Paulo, Brazil, 05508-030
        • Institute of Psychology, University of São Paulo
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 59 years (Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Adults aged 18 to 59 years.
  • Clinically significant symptoms in at least one of the following domains at screening:
  • Insomnia: Insomnia Severity Index (ISI) score ≥11;
  • Depression: Patient Health Questionnaire-9 (PHQ-9) score ≥10;
  • Anxiety: Generalized Anxiety Disorder-7 (GAD-7) score ≥10.
  • Residence in Brazil.
  • Ability to read and understand written Portuguese.
  • Regular access to WhatsApp on a personal device.
  • Willingness and availability to participate in the intervention and complete the scheduled study assessments.
  • Provision of electronic informed consent.

Exclusion Criteria:

  • Current diagnosis of bipolar disorder or psychotic disorder, or severe suicide risk.
  • Substance use disorder that would substantially interfere with participation in the intervention or completion of study assessments.
  • Severe and unstable neurological or medical conditions, such as dementia or advanced-stage cancer.
  • Night-shift work that cannot be reorganized.
  • Significant cognitive impairment that would hinder participation in the digital intervention.
  • Unavailability to participate in the intervention or complete the scheduled study assessments.
  • Use of sleep medication, either regularly or intermittently, without a stable medication use pattern for at least 2 months before enrollment, including recent initiation or substantial changes in the regimen.
  • Use of antidepressants or other psychotropic medications intended for regular use without a stable regimen for at least 1 month following a dose adjustment or 2 months following initiation of a new medication.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Vínculo Digital Intervention

Participants will receive Vínculo, an eight-week guided digital transdiagnostic psychological intervention delivered through a WhatsApp chatbot. The intervention integrates acceptance and commitment therapy, behavioral activation, and behavioral sleep strategies. Structured content will be delivered on Mondays, Wednesdays, and Fridays, with reminders on Tuesdays, Thursdays, and Saturdays. Participants will also receive three individual videoconference sessions with a psychologist (before treatment, Week 4, and Week 8) and asynchronous psychological support on business days (Monday to Friday).

Vínculo is an eight-week guided digital transdiagnostic psychological intervention delivered through a WhatsApp chatbot. Based on process-based therapy, it integrates acceptance and commitment therapy, behavioral activation, and behavioral sleep regulation. Components include mindfulness, acceptance, cognitive defusion, values clarification, committed action, and behavioral activation. Sleep-related content is addressed throughout the intervention, including psychoeducation, stimulus control, a consistent wake time, daytime activity, morning natural light exposure, and a wind-down routine. Content is delivered three times weekly, with reminders on alternate days. Participants receive three individual videoconference sessions with a psychologist (before treatment, Week 4, and Week 8) and asynchronous psychological support on business days.

Active Comparator: Digital Psychoeducation

Participants will receive an eight-week digital psychoeducation program delivered through a WhatsApp chatbot. The program provides information about mental health, emotional symptoms, sleep, and healthy lifestyle habits, without introducing the specific therapeutic techniques used in the experimental intervention. Structured content will be delivered on Mondays, Wednesdays, and Fridays, with reminders on Tuesdays, Thursdays, and Saturdays. Participants will also receive three individual videoconference sessions with a psychologist (before treatment, Week 4, and Week 8) and asynchronous professional support on business days (Monday to Friday), limited to clarifying psychoeducational content, addressing technical difficulties, and supporting engagement.

An eight-week digital psychoeducation program delivered through a WhatsApp chatbot. The program provides structured information about mental health, emotional symptoms, sleep, and healthy lifestyle habits, without introducing the specific therapeutic techniques of the experimental intervention. Content is delivered three times weekly, with reminders on alternate days. Participants receive three individual videoconference sessions with a psychologist (before treatment, Week 4, and Week 8) and asynchronous professional support on business days. Professional support is limited to clarifying psychoeducational content, addressing technical difficulties, and supporting engagement.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Insomnia Symptom Severity (Insomnia Severity Index - ISI)
Time Frame: One week after completion of the 8-week intervention

The Insomnia Severity Index (ISI) is a seven-item self-report questionnaire assessing insomnia symptom severity. Total scores range from 0 to 28, with higher scores indicating greater insomnia severity. The primary outcome is the ISI total score at post-treatment, adjusted for baseline severity.

One week after completion of the 8-week intervention
Depressive Symptom Severity (Patient Health Questionnaire-9 - PHQ-9)
Time Frame: One week after completion of the 8-week intervention

The Patient Health Questionnaire-9 (PHQ-9) is a nine-item self-report questionnaire assessing depressive symptom severity. Total scores range from 0 to 27, with higher scores indicating greater depressive symptom severity. The primary outcome is the PHQ-9 total score at post-treatment, adjusted for baseline severity.

One week after completion of the 8-week intervention
Anxiety Symptom Severity (Generalized Anxiety Disorder-7 - GAD-7)
Time Frame: One week after completion of the 8-week intervention

The Generalized Anxiety Disorder-7 (GAD-7) is a seven-item self-report questionnaire assessing anxiety symptom severity. Total scores range from 0 to 21, with higher scores indicating greater anxiety severity. The primary outcome is the GAD-7 total score at post-treatment, adjusted for baseline severity.

One week after completion of the 8-week intervention

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Insomnia Symptom Severity at Follow-up (Insomnia Severity Index - ISI)
Time Frame: 3 and 6 months after completion of the 8-week intervention

The Insomnia Severity Index (ISI) is a seven-item self-report questionnaire assessing insomnia symptom severity. Total scores range from 0 to 28, with higher scores indicating greater insomnia severity. ISI total scores will be assessed at the 3-month and 6-month follow-ups to evaluate maintenance of treatment effects, adjusting for baseline severity.

3 and 6 months after completion of the 8-week intervention
Depressive Symptom Severity at Follow-up (Patient Health Questionnaire-9 - PHQ-9)
Time Frame: 3 and 6 months after completion of the 8-week intervention

The Patient Health Questionnaire-9 (PHQ-9) is a nine-item self-report questionnaire assessing depressive symptom severity. Total scores range from 0 to 27, with higher scores indicating greater depressive symptom severity. PHQ-9 total scores will be assessed at the 3-month and 6-month follow-ups to evaluate maintenance of treatment effects, adjusting for baseline severity.

3 and 6 months after completion of the 8-week intervention
Anxiety Symptom Severity at Follow-up (Generalized Anxiety Disorder-7 - GAD-7)
Time Frame: 3 and 6 months after completion of the 8-week intervention

The Generalized Anxiety Disorder-7 (GAD-7) is a seven-item self-report questionnaire assessing anxiety symptom severity. Total scores range from 0 to 21, with higher scores indicating greater anxiety severity. GAD-7 total scores will be assessed at the 3-month and 6-month follow-ups to evaluate maintenance of treatment effects, adjusting for baseline severity.

3 and 6 months after completion of the 8-week intervention
Functional Impairment (Sheehan Disability Scale - SDS)
Time Frame: One week after completion of the 8-week intervention, and at 3- and 6-month follow-ups

The Sheehan Disability Scale (SDS) is a three-item self-report measure assessing functional impairment in work or school, social life, and family life or home responsibilities. Each domain is scored from 0 to 10, with a total score ranging from 0 to 30. Higher scores indicate greater functional impairment.

One week after completion of the 8-week intervention, and at 3- and 6-month follow-ups
Behavioral Activation (Behavioral Activation for Depression Scale - Short Form, BADS-SF)
Time Frame: Week 4, one week after completion of the 8-week intervention, and at 3- and 6-month follow-ups

The Behavioral Activation for Depression Scale - Short Form (BADS-SF) is a nine-item self-report measure assessing behavioral activation and avoidance. Total scores range from 0 to 54, with higher scores indicating greater behavioral activation. Changes in behavioral activation will be evaluated across the scheduled assessments.

Week 4, one week after completion of the 8-week intervention, and at 3- and 6-month follow-ups
Psychological Flexibility (Comprehensive Assessment of Acceptance and Commitment Therapy Processes - CompACT)
Time Frame: Week 4, one week after completion of the 8-week intervention, and at 3- and 6-month follow-ups

The Comprehensive Assessment of Acceptance and Commitment Therapy Processes (CompACT) is a 23-item self-report measure assessing psychological flexibility through openness to experience, behavioral awareness, and valued action. Total scores range from 0 to 138, with higher scores indicating greater psychological flexibility.

Week 4, one week after completion of the 8-week intervention, and at 3- and 6-month follow-ups
Clinical Response in Insomnia Symptoms (ISI)
Time Frame: One week after completion of the 8-week intervention, and at 3- and 6-month follow-ups

Clinical response in insomnia symptoms will be defined as a reduction of at least 8 points in the Insomnia Severity Index (ISI) total score relative to baseline. The outcome will be expressed as the proportion of participants meeting this predefined response criterion at each assessment.

One week after completion of the 8-week intervention, and at 3- and 6-month follow-ups
Clinical Response in Depressive Symptoms (PHQ-9)
Time Frame: One week after completion of the 8-week intervention, and at 3- and 6-month follow-ups

Clinical response in depressive symptoms will be defined as a reduction of at least 50% in the Patient Health Questionnaire-9 (PHQ-9) total score relative to baseline. The outcome will be expressed as the proportion of participants meeting this predefined response criterion at each assessment.

One week after completion of the 8-week intervention, and at 3- and 6-month follow-ups
Clinical Response in Anxiety Symptoms (GAD-7)
Time Frame: One week after completion of the 8-week intervention, and at 3- and 6-month follow-ups

Clinical response in anxiety symptoms will be defined as a reduction of at least 50% in the Generalized Anxiety Disorder-7 (GAD-7) total score relative to baseline. The outcome will be expressed as the proportion of participants meeting this predefined response criterion at each assessment.

One week after completion of the 8-week intervention, and at 3- and 6-month follow-ups

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Anhedonia (Snaith-Hamilton Pleasure Scale - SHAPS)
Time Frame: One week after completion of the 8-week intervention, and at 3- and 6-month follow-ups

The Snaith-Hamilton Pleasure Scale (SHAPS) is a 14-item self-report questionnaire assessing anhedonia, defined as a reduced capacity to experience pleasure. Using conventional dichotomous scoring, total scores range from 0 to 14, with higher scores indicating greater anhedonia. Changes in anhedonia will be evaluated as an exploratory outcome.

One week after completion of the 8-week intervention, and at 3- and 6-month follow-ups
Therapeutic Alliance (Working Alliance Inventory for Guided Internet Interventions - WAI-I)
Time Frame: Week 4 and one week after completion of the 8-week intervention

The Working Alliance Inventory for Guided Internet Interventions (WAI-I) is a self-report measure assessing the therapeutic alliance in guided internet-based psychological interventions, including agreement on therapeutic goals, agreement on tasks, and the therapeutic bond. Higher scores indicate a stronger therapeutic alliance. Therapeutic alliance will be evaluated as an exploratory outcome.

Week 4 and one week after completion of the 8-week intervention

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Collaborators

Investigators

  • Principal Investigator: Renatha El Rafihi-Ferreira, PhD, University of Sao Paulo

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

May 1, 2027

Primary Completion (Estimated)

July 1, 2029

Study Completion (Estimated)

November 1, 2029

Study Registration Dates

First Submitted

November 15, 2026

First Submitted That Met QC Criteria

November 15, 2026

First Posted (Actual)

November 20, 2026

Study Record Updates

Last Update Posted (Actual)

November 20, 2026

Last Update Submitted That Met QC Criteria

November 15, 2026

Last Verified

November 1, 2026

More Information

Terms related to this study

Other Study ID Numbers

  • CISM-VINCULO-ADI

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

IPD Plan Description

Individual participant data sharing has not yet been determined. Study data will be securely stored, and access will be restricted to authorized research personnel in accordance with institutional policies, ethical approvals, and Brazilian data protection legislation. The possibility of sharing de-identified participant data for scientific purposes will be evaluated in accordance with applicable ethical and institutional requirements.

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.